ALB and Sepsis: However, inconsistent with the CRISTAL randomized trial, which showed a lower mortality rate after albumin therapy for patients with sepsis at 90-day mortality (34), our study found no difference between the two groups regarding 90-day mortality survival benefits in septic patients with CHD.